Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36617420)

  • 1. The expression of HER2/neu in patients with lung cancer and its associated factors.
    Lashkarizadeh M; Lashkarizadeh M; Nikian M; Kouhestani Parizi M
    Clin Respir J; 2023 Feb; 17(2):90-95. PubMed ID: 36617420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: strong thyroid transcription factor-1 expression predicts better survival.
    Haque AK; Syed S; Lele SM; Freeman DH; Adegboyega PA
    Appl Immunohistochem Mol Morphol; 2002 Jun; 10(2):103-9. PubMed ID: 12051626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.
    Onn A; Correa AM; Gilcrease M; Isobe T; Massarelli E; Bucana CD; O'Reilly MS; Hong WK; Fidler IJ; Putnam JB; Herbst RS
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):136-43. PubMed ID: 14734462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in the predictive power of the molecular prognostic factor HER2/neu in patients with non-small-cell lung cancer.
    Vallböhmer D; Brabender J; Yang DY; Danenberg K; Schneider PM; Metzger R; Holscher AH; Danenberg PV
    Clin Lung Cancer; 2006 Mar; 7(5):332-7. PubMed ID: 16640805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations.
    Zhuo X; Guo H; Ma J; Lai J; Liu L; Yin K; Zhao J; Wang J; Jiang F; Xu W; Yuan X; Lin X; Fu G
    J Cancer Res Clin Oncol; 2023 May; 149(5):2029-2039. PubMed ID: 35829744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of HER2 overexpression in non-small cell lung cancer.
    Takenaka M; Hanagiri T; Shinohara S; Kuwata T; Chikaishi Y; Oka S; Shigematsu Y; Nagata Y; Shimokawa H; Nakagawa M; Uramoto H; So T; Tanaka F
    Anticancer Res; 2011 Dec; 31(12):4631-6. PubMed ID: 22199341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.
    Brabender J; Danenberg KD; Metzger R; Schneider PM; Park J; Salonga D; Hölscher AH; Danenberg PV
    Clin Cancer Res; 2001 Jul; 7(7):1850-5. PubMed ID: 11448895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Human Epidermal Growth Factor Receptor (Her 2/neu) and Proliferative Marker Ki-67: Association with Clinicopathological Parameters in Gallbladder Carcinoma.
    Pujani M; Makker I; Makker A; Jetley S; Goel MM; Jetley S
    Asian Pac J Cancer Prev; 2016; 17(8):3903-9. PubMed ID: 27644637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
    Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
    Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human epidermal growth factor receptor 2 neu expression in head and neck squamous cell cancers and its clinicopathological correlation: Results from an Indian cancer center.
    Vats S; Ganesh MS; Agarwal A
    Indian J Pathol Microbiol; 2018; 61(3):313-318. PubMed ID: 30004046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu.
    Ren XL; Xu YM; Bao W; Fu HJ; Wu CG; Zhao Y; Li ZK; Zhang J; Li SQ; Chen WQ; Wang T; Zhang R; Zhang LH; Qian GS; Chen SY; Jia LT; Yang AG
    Cancer Lett; 2009 Aug; 281(2):134-43. PubMed ID: 19339104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
    Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
    Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of HER2/neu status in Qatari women with breast carcinoma.
    Rasul KI; Mohammaed K; Abdalla AS; Chong-Lopez A; Ahmad MA; Al-Homsi MU; Al-Hassan AM; Al-Alosi AS; Bener A
    Saudi Med J; 2003 Aug; 24(8):832-6. PubMed ID: 12939666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers.
    Tomizawa K; Suda K; Onozato R; Kosaka T; Endoh H; Sekido Y; Shigematsu H; Kuwano H; Yatabe Y; Mitsudomi T
    Lung Cancer; 2011 Oct; 74(1):139-44. PubMed ID: 21353324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p95HER2 truncated form in resected non-small cell lung cancer.
    Cappuzzo F; Cho YG; Sacconi A; Alì G; Siclari O; Incarbone M; Destro A; Terracciano L; Fontanini G; Marchetti A; Roncalli M; Varella-Garcia M
    J Thorac Oncol; 2012 Mar; 7(3):520-7. PubMed ID: 22307009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma].
    Song Y; Huang J; Wang JW
    Chin J Cancer; 2010 Jan; 29(1):76-81. PubMed ID: 20038314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.
    Shokouh TZ; Ezatollah A; Barand P
    Medicine (Baltimore); 2015 Aug; 94(32):e1359. PubMed ID: 26266392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative real-time PCR assay with immunohistochemical evaluation of HER2/neu oncogene in breast cancer patients and its correlation with clinicopathological findings.
    Gheni N; Westenberg D
    Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S123-S128. PubMed ID: 32108644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.